Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.

Paul J M WijnkerRafeeh DinaniNico C van der LaanSila AlgülBjorn C KnollmannArjan C HouwelingCarol Ann RemmeCoert J ZuurbierDiederik W D KusterJolanda van der Velden

Published in: Cardiovascular research (2024)

SGLT2i (canagliflozin > dapagliflozin > empagliflozin) acutely enhance relaxation in human EHT, especially in HCM and upon prolonged culture. SGLT2i may represent a potential therapy to correct early cardiac dysfunction in HCM.

Keyphrases

hypertrophic cardiomyopathy
left ventricular
endothelial cells
oxidative stress
induced pluripotent stem cells
heart failure
risk assessment
bone marrow
climate change
chemotherapy induced